Contract research and manufacturing company Syngene International has had a fabulous run this year. Its stock price has risen over 40% since January amid robust growth and a positive outlook for the business. Syngene’s market capitalisation has reached INR33,000 crore, surpassing the INR32,600 crore market cap of its parent company Biocon. Since its listing in 2015, the Syngene stock has been rising steadily. Its market cap touched INR20,000
Related Posts
Cipla takeover: Torrent Pharma is gearing up to take over Cipla. Here’s why it’s a tightrope walk.
Synopsis If Torrent Pharma were to acquire Cipla, which is 2.5 times its size in sales, it would be a bold move. While the acquisition would catapult Torrent to the top of the heap in the domestic market and make it the second-largest Indian pharma company in terms of revenue, financing the deal and integration […]
These bugs are killing 5 million every year, yet doctors have few options to fight them
Doctors are grappling with a raft of unsparing hospital-acquired superbugs broadly known as anti-microbial resistance or AMR. Are bacterial infections the next big lethal adversary for mankind?
Piramal Pharma Stock: Piramal Pharma expects healthy growth in its key businesses. But does it cure the debt ailment?
Nandini Piramal, chairperson, Piramal Pharma; image courtesy of Piramal Pharma. Synopsis Piramal Pharma’s management is optimistic that with revenue growth and margin expansion, it will be able to trim debt over the next five years. But the capital-intensive nature of its main contract manufacturing business scaling remains a challenge. Will Piramal Pharma be able to […]
